Year: 2020

There are currently no approved treatments or vaccines for the coronavirus, which has infected 2.14 million globally, according to a Reuters tally, and remdesivir is one of the treatments that has captured investor’s attention. Gilead said the totality of the data from the trial needed to be analyzed, and expects to report results from a study in severe COVID-19 patients at the end of the month, and data from other trials in May. The report said the University of Chicago Medicine Hospital was seeing rapid recoveries in fever and respiratory symptoms in patients with severe COVID-19 in a …read more […]

(Bloomberg) — Apple Inc. could see the number of iPhones sold slump by more than a third in the second quarter of the year, Goldman Sachs estimates, downgrading its recommendation on the stock to sell from neutral.Unit sales for iPhones are set to drop by 36% year-on-year in the second quarter as the economy takes a hit from the pandemic, before recovering to just a 2% decline by the fourth quarter of this year, analysts including Rod Hall wrote in a note. Weakness for average selling prices is also likely to linger, he said. Hall cut his price target on …read more […]

Some analysts have cautioned investors to curb their enthusiasm over Gilead’s coronavirus treatment, and the potential for it to be effective on a broader scale. …read more […]

After almost 4 weeks of bullish trading, investors are growing used to the idea that we’re in a true rally. Yes, markets are still down from their February peak; yes, the coronavirus epidemic is still going strong; and yes, the lockdowns in place to combat the virus’ spread are still wreaking havoc on the economy – but for now, at least, the stock markets are trending up.On Wall Street, Chris Harvey, Wells Fargo’s head of equity strategy, sees opportunities in current market conditions. “Destruction in stock prices has really uncovered a significant amount of value,” Harvey says, although he does …read more […]

This article is written for those who want to get better at using price to earnings ratios (P/E ratios). We’ll look at… …read more […]

The biggest U.S. planemaker soared 11.2% in premarket trading after saying it would resume commercial aircraft production next week in Washington state after halting operations last month due to the coronavirus pandemic. Late on Thursday, Trump outlined a plan to ease the shutdown in a staggered, three-stage process, but the plan was a set of recommendations rather than orders and left the decision largely up to state governors. Gilead Sciences Inc surged 11% following a media report that patients with severe symptoms of the disease had responded positively to its experimental drug, remdesivir. …read more […]

(Bloomberg) — Gold has rarely been a hotter trade, but the world’s two most important markets remain out of sync. In New York, the price of gold topped $1,750 for the first time in seven years on April 9. In London, it still hasn’t caught up.The dislocation first blew out in late March, when disruptions from the coronavirus sparked concerns among traders about getting gold to New York in time to settle futures contracts. In a chaotic couple of days, the premium for New York futures over the London spot price rose above $70 — the highest in four decades.The …read more […]